Stevanato Group (STVN) Stock Price, News & Analysis

Company Overview

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Key Stats

• Today's Range: €20.07 to €21.09
• 50-Day Range: €17.90 to €22.52
• 52-Week Range: €16.56 to €31.41
• Volume: 867,100 shs
• Average Volume: 351,970 shs
• Market Capitalization: $6.14 billion
• P/E Ratio: 43.15
• Dividend Yield: 0.30%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Stevanato Group Stock Analysis - MarketRank™

Stevanato Group scored higher than 33% of companies evaluated by MarketBeat, and ranked 737th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Stevanato Group.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 16.00%

Earnings Growth

Earnings for Stevanato Group are expected to grow by 16.00% in the coming year, from €0.50 to €0.58 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Stevanato Group is 43.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.68.

Price to Earnings Ratio vs. Sector

The P/E ratio of Stevanato Group is 43.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.22.

Price to Earnings Growth Ratio

Stevanato Group has a PEG Ratio of 7.18. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Stevanato Group has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.75% of the float of Stevanato Group has been sold short.

Short Interest Ratio / Days to Cover

Stevanato Group has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Stevanato Group has recently decreased by 4.56%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Stevanato Group has a dividend yield of 0.27%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Stevanato Group does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Stevanato Group is 12.50%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Stevanato Group will have a dividend payout ratio of 10.34% next year. This indicates that Stevanato Group will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.75% of the float of Stevanato Group has been sold short.

Short Interest Ratio / Days to Cover

Stevanato Group has a short interest ratio ("days to cover") of 9.2.

Change versus previous month

Short interest in Stevanato Group has recently decreased by 4.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.74

News Sentiment

Stevanato Group has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Stevanato Group this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for STVN on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Stevanato Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.70% of the stock of Stevanato Group is held by insiders.

STVN Stock Analysis - Frequently Asked Questions

How have STVN shares performed this year?

Stevanato Group's stock was trading at €21.79 at the beginning of the year. Since then, STVN shares have decreased by 6.9% and is now trading at €20.28.
View the best growth stocks for 2025 here.

How were Stevanato Group's earnings last quarter?

Stevanato Group S.p.A. (NYSE:STVN) issued its earnings results on Thursday, March, 6th. The company reported $0.20 earnings per share for the quarter, hitting the consensus estimate of $0.20. The business earned $352.68 million during the quarter, compared to analyst estimates of $346.26 million. Stevanato Group had a trailing twelve-month return on equity of 9.86% and a net margin of 10.47%.

When did Stevanato Group IPO?

Stevanato Group (STVN) raised $720 million in an initial public offering on Friday, July 16th 2021. The company issued 32,000,000 shares at $21.00-$24.00 per share.

How do I buy shares of Stevanato Group?

Shares of STVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Stevanato Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Stevanato Group investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Fortinet (FTNT), Antero Resources (AR), CrowdStrike (CRWD), Walt Disney (DIS) and Onsemi (ON).

Company Calendar

• Last Earnings: 3/06/2025
• Today: 4/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:STVN
• CIK: 1849853
• Web: www.stevanatogroup.com
• Phone: 39049931811
• Fax: N/A
• Employees: 4,650
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): €0.48
• Trailing P/E Ratio: 43.15
• Forward P/E Ratio: 40.56
• P/E Growth: 7.18
• Net Income: $157.62 million
• Net Margins: 10.47%
• Pretax Margin: 14.11%
• Return on Equity: 9.86%
• Return on Assets: 5.79%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 1.81
• Quick Ratio: 1.21

Sales & Book Value

• Annual Sales: $1.10 billion
• Price / Sales: 5.56
• Cash Flow: €0.85 per share
• Price / Cash Flow: 23.97
• Book Value: €4.15 per share
• Price / Book: 4.89

Miscellaneous

• Outstanding Shares: 302,843,000
• Free Float: 300,723,000
• Market Cap: $6.14 billion
• Optionable: Optionable
• Beta: 0.60